

Title (en)

PHARMACEUTICAL COMPOSITION FOR DIAGNOSIS, PREVENTION OR TREATMENT OF A TUMOROUS STATE, COMPRISING A MODULATOR OF THE ACTIN POLYMERISATION STATE

Title (de)

PHARMAZEUTISCHE ZUSAMMENSETZUNG DIE EIN MODULATOR DES POLYMERISATIONS-ZUSTANDES VON AKTIN ENTHALTET

Title (fr)

COMPOSITION PHARMACEUTIQUE COMPRENANT UN AGENT MODULATEUR DE L'ETAT DE POLYMERISATION DE L'ACTINE

Publication

**EP 1432732 A2 20040630 (FR)**

Application

**EP 02745538 A 20020618**

Priority

- FR 0202106 W 20020618
- FR 0107976 A 20010618

Abstract (en)

[origin: FR2825928A1] Composition (A) for treatment, prevention and diagnosis of a tumor comprising an agent (I) that can stabilize the actin network of the cytoskeleton, is new. Independent claims are also included for the following: (1) non-viral vector of intracellular transport (B) associated with (I); (2) vector of intracellular transport (B') comprising a recombinant viral expression vector that includes cDNA representing the zyxin gene, or its functional fragment; (3) cell genetically modified to over- or under-express the zyxin gene; (4) transgenic mammal containing at least one cell modified for underexpression of the zyxin gene; (5) identifying (I); (6) diagnosis of tumors by quantifying expression of zyxin in patient cells; (7) phenotypic analysis of tumors by quantifying zyxin at different times and comparing expression levels to produce a differential phenotypic profile; and (8) screening compounds for antitumor activity based on measuring the stabilization of the polymerization of the actin framework in tumor cells.

IPC 1-7

**C07K 14/47**; **A61K 38/17**; **C12N 5/10**; **A61K 31/713**; **A61K 38/12**; **A61K 48/00**; **G01N 33/50**; **G01N 33/68**; **A61P 35/00**

IPC 8 full level

**A01K 67/027** (2006.01); **A61K 35/12** (2015.01); **A61K 35/28** (2015.01); **A61K 35/76** (2015.01); **A61K 35/761** (2015.01); **A61K 38/00** (2006.01); **A61K 45/00** (2006.01); **A61K 48/00** (2006.01); **A61P 7/00** (2006.01); **A61P 35/00** (2006.01); **C07K 14/47** (2006.01); **C12N 5/10** (2006.01); **C12N 15/09** (2006.01); **C12N 15/113** (2010.01); **C12Q 1/02** (2006.01); **C12Q 1/68** (2006.01); **G01N 33/15** (2006.01); **G01N 33/50** (2006.01); **G01N 33/68** (2006.01)

CPC (source: EP US)

**A61P 7/00** (2018.01 - EP); **A61P 35/00** (2018.01 - EP); **C07K 14/47** (2013.01 - EP US); **C12N 15/113** (2013.01 - EP US)

Citation (examination)

WO 0033888 A2 20000615 - COULTER PHARM INC [US], et al

Designated contracting state (EPC)

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

DOCDB simple family (publication)

**FR 2825928 A1 20021220**; **FR 2825928 B1 20040402**; AU 2002317259 A1 20030102; CA 2450845 A1 20021227; EP 1432732 A2 20040630; JP 2005504521 A 20050217; JP 4271026 B2 20090603; US 2004191230 A1 20040930; US 2009286720 A1 20091119; WO 02102846 A2 20021227; WO 02102846 A3 20040422; WO 02102846 B1 20040603

DOCDB simple family (application)

**FR 0107976 A 20010618**; AU 2002317259 A 20020618; CA 2450845 A 20020618; EP 02745538 A 20020618; FR 0202106 W 20020618; JP 2003506318 A 20020618; US 42683309 A 20090420; US 74026603 A 20031218